Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


12 Nov 2016 - 16 Nov 2016
16 Nov 2016 - 19 Nov 2016

GE Healthcare to Be Sole Distributor of Gyros' Nanoliter-Scale Immunoassay Platform in Japan

By BiotechDaily International staff writers
Posted on 20 Jul 2011
Print article
GE Healthcare Life Sciences (Little Chalfont, UK), a global provider of transformational medical technologies and services, has signed a sole distribution agreement with Gyros AB (Uppsala, Sweden), a developer of microfluidic technologies to miniaturize and automate immunoassays. Under the agreement, GE Healthcare becomes the sole distributor of the Gyros nanoliter-scale immunoassay platform in Japan.

Major biopharmaceutical companies and their service providers use the Gyros platform worldwide to improve productivity and efficiency when developing biotherapeutics and vaccines, generating time-critical workflows to meet regulatory demands.

Erik Walldén, CEO at Gyros, said, “The growing acceptance of our nanoliter-scale immunoassay platform within the global biopharmaceutical industry makes it imperative that we are represented within the Japanese market. We believe that this agreement with GE Healthcare Life Sciences will be a key factor in our success. As well as the clear commercial synergy between our product portfolios, we can be sure of providing the highest standards of service and support for our Japanese customers. We look forward to a highly successful collaboration.”

Hiroko Watanabe, general manager GE Healthcare Life Sciences, Japan, added, “We are delighted to have signed this agreement with Gyros which will help us expand our offering of value-added and innovative technologies to the biopharmaceutical industry in Japan. The Gyros immunoassay platform offers manufacturers of biopharmaceuticals and vaccines the potential to make substantial improvements in productivity and is an excellent complement to our own extensive range of analytical technologies for the biopharmaceutical industry.”

Related Links:

GE Healthcare Life Sciences

Print article


Drug Discovery

view channel
Image: Positive alpha-synuclein staining of a Lewy body from a patient with Parkinson\'s disease (Photo courtesy of Wikimedia Commons).

Bifunctional Dimer Drugs Prove Effective in Parkinson's Disease Yeast Model

A team of Canadian neurodegenerative disease researchers used a yeast model system to identify novel drug compounds that were able to block the misfolding of alpha- synuclein (AS) protein, which characterizes... Read more


view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.